deaths (OS)

metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)

versus cabozantinib
atezolizumab plus cabozantinib vs. cabozantinib 1 certainty unassessable-6%